(Q43172775)

15 November 2017

title

Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression (English)

1 reference

15 November 2017

0 references

1 reference

9

Daniel Podzamczer

1 reference

15 November 2017

Bonaventura Clotet Sala

10

object named as

Bonaventura Clotet

1 reference

15 November 2017

José R Santos

1

1 reference

15 November 2017

Josep M Llibre

2

1 reference

15 November 2017

Elena Ferrer

3

1 reference

15 November 2017

Pere Domingo

4

1 reference

15 November 2017

Arkaitz Imaz

5

1 reference

15 November 2017

José Moltó

6

1 reference

15 November 2017

Raquel Martin-Iguacel

7

1 reference

15 November 2017

Carme Caum

8

1 reference

15 November 2017

publication date

1 November 2009

1 reference

15 November 2017

1 reference

15 November 2017

volume

10

1 reference

15 November 2017

issue

6

1 reference

15 November 2017

page(s)

432-438

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

The fusion inhibitor enfuvirtide in recent antiretroviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-432

21 January 2018

Identifiers

DOI

10.1310/HCT1006-432

1 reference

15 November 2017

1 reference